User menu

Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment

Bibliographic reference Schwenkglenks, Matthias ; Jackisch, Christian ; Constenla, Manuel ; Kerger, Joseph ; Paridaens, Robert ; et. al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. In: Supportive Care in Cancer, Vol. 14, no. 9, p. 901-909 (2006)
Permanent URL
  1. Balducci L (2003) Myelosuppression and its consequences in elderly patients with cancer. Oncology (Huntingt) 17:27–32
  2. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901–906
  3. Budman DR, Berry DA, Cirrincione CT et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205–1211
  4. Chang J (2000) Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36(Suppl 1):S11–S14
  5. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439
  6. Constenla M, Bosly A, Jackisch C et al (2003) An audit of primary breast cancer management in Spain: the OSQAR study [abstract]. Proc Am Soc Clin Oncol 22:312
  7. Crawford Jeffrey, Ozer Howard, Stoller Ronald, Johnson David, Lyman Gary, Tabbara Imad, Kris Mark, Grous John, Picozzi Vincent, Rausch Gregory, Smith Roy, Gradishar William, Yahanda Anne, Vincent Martha, Stewart Morgan, Glaspy John, Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer, 10.1056/nejm199107183250305
  8. Dale DC, Crawford J, Lyman CG (2001) Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review [abstract]. Proc Am Soc Clin Oncol 20:1638
  9. Dale DC (2002) Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62(Suppl 1):1–15
  10. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942
  11. Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T (2002) Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 20:3637–3643
  12. Engelsman E, Klijn JC, Rubens RD et al (1991) “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27:966–970
  13. ESMO Guidelines Task Force (2001) ESMO recommendations for the application of haematopoietic growth factors (hGFs). Ann Oncol 12:1219–1220
  14. Hryniuk W, Frei E 3rd, Wright FA (1998) A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 16:3137–3147
  15. Jackisch C, Jaber M, Burkamp U et al (2003) Maintenance of dose intensity in adjuvant chemotherapy of breast cancer in patients treated outside a clinical trial. Results of a retrospective study. Geburtshilfe Frauenheilkd 63:333–343
  16. Kerger JN, Bormans V, Dauwe M (2002) Adjuvant (adj) chemotherapy (CT) delivery in patients (pts) with breast cancer (BC): results from the Chemodose Working Party Belgium–Luxembourg [abstract]. Ann Oncol 13(Suppl 5):38
  17. Leonard RC, Miles D, Thomas R, Nussey F (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89:2062–2068
  18. Link BK, Budd GT, Scott S et al (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92:1354–1367
  19. Lyman GH (2003) Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Huntingt) 17:8–13
  20. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531
  21. National Comprehensive Cancer Network (NCCN) (2005) Clinical Practice Guidelines in Oncology—v.2.2005. Myeloid growth factors in cancer treatment. . Accessed May 30, 2005
  22. Ozer H, Armitage JO, Bennett CL et al (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558–3585
  23. Piccart MJ, Biganzoli L, Di Leo A (2000) The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 36(Suppl 1):S4–S10
  24. Rogers WH (1993) Regression standard errors in clustered samples. Stata Tech Bull 13:19–23
  25. Silber JH, Fridman M, DiPaola RS et al (1998) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16:2392–2400
  26. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322
  27. Thatcher N, Girling DJ, Hopwood P et al (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395–404